2025
Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer.
Hrinczenko B, Adeyelu T, Wei W, Elliott A, Bepler G, Vanderwalde A, Halmos B, Antonarakis E, Lustberg M, Jacob J. Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer. Journal Of Clinical Oncology 2025, 43: 2633-2633. DOI: 10.1200/jco.2025.43.16_suppl.2633.Peer-Reviewed Original ResearchNon-small cell lung cancerSmall cell lung cancerImmune checkpoint inhibitorsMetastatic non-small cell lung cancerProgression-free survivalCell lung cancerOverall survivalLung cancerLILRB4 expressionICI responsePrimary non-small cell lung cancerMetastatic small cell lung cancerSuppress adaptive immune responsesAssociated with improved survivalICI-treated patientsAssociated with OSImprove survival outcomesAdaptive immune responsesLung cancer typesDatasets of non-small cell lung cancerAnti-inflammatory pathwayLung cancer survivalAtezolizumab treatmentTSC22D3 expressionCheckpoint inhibitorsBaseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.
Nawfal R, El Hajj Chehade R, Semaan K, Eid M, Ascione L, Saad E, Daoud Khatoun W, Jamal Saleh M, El Masri J, Xu W, Yekeduz E, Sun M, Braun D, Gupta S, Heng D, Krajewski K, Choueiri T. Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial. Journal Of Clinical Oncology 2025, 43: 4544-4544. DOI: 10.1200/jco.2025.43.16_suppl.4544.Peer-Reviewed Original ResearchProgression-free survivalMetastatic renal cell carcinomaIMDC risk groupsPoor-risk groupAssociated with OSOverall survivalTumor burdenRisk groupsMultivariate analysisRandomized prospective phase III studyProgression-free survival eventsProspective phase III studyAssociated with worse OSRandomized phase III trialMultivariate Cox regression modelBaseline tumor burdenCheckMate 9ER trialPoor-risk subgroupsFavorable risk groupRoutine CT scansFirst-line therapyPhase III studyIntermediate risk groupPhase III trialsRenal cell carcinomaProstate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis
Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025 PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsPSA responseProstate-specific antigen reductionAssociated with better OSProstate-specific antigenAndrogen deprivation therapyCastration-resistant PCOverall survivalProstate cancerTreated with androgen deprivation therapyHazard ratioMetastatic castration-resistant PCMetastatic hormone-sensitive PCNonmetastatic castration-resistant PCProstate-specific antigen responsePathway inhibitorBaseline PSA measurementHormone-sensitive PCUndetectable PSA levelsAdvanced prostate cancerAssociated with OSRandom-effects meta-analysesDeprivation therapyPSA levelsPSA measurements
2024
20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study
Saliby R, Xie W, Wells C, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Ravi P, Suarez C, Morales J, McKay R, Powles T, Wood L, Lalani A, Pal S, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. The Oncologist 2024, 29: s8-s9. PMCID: PMC11301915, DOI: 10.1093/oncolo/oyae181.013.Peer-Reviewed Original ResearchTime to next therapyInternational mRCC Database ConsortiumTime to treatment failureInternational mRCC Database Consortium risk groupOverall survivalObjective responseFollow-upIndividual patient dataLandmark analysisTreatment failureInternational Metastatic Renal-Cell Carcinoma Database ConsortiumMetastatic renal cell carcinoma treated with immune checkpoint inhibitorsRisk groupsEndpoint of overall survivalMonths of follow-upIntermediate endpointsICI-based regimensImmune checkpoint inhibitorsImmune-checkpoint inhibitorsMedian Follow-UpAnalysis of OSAssociated with OSAssociation of OSPost-therapy initiationFollow-up timeImpact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Skelton W, Masur J, Thomas J, Fallah P, Jain R, Ravi P, Mantia C, McGregor B, Nuzzo P, Adib E, Zarif T, Preston M, Clinton T, Li R, Steele G, Kassouf W, Freeman D, Pond G, Jain R, Sonpavde G. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102143. PMID: 39032202, DOI: 10.1016/j.clgc.2024.102143.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerPathological complete responsePathologic complete response rateRenin-angiotensin systemNeoadjuvant chemotherapyAngiotensin-converting enzyme inhibitorsConverting Enzyme InhibitorsOverall survivalRadical cystectomyPerformance statusClinical stageComplete responseBladder cancerAssociated with increased pCRAssociated with pathologic complete responseFemale sexAssociated with improved OSImpact of angiotensin-converting enzyme inhibitorsCycles of neoadjuvant chemotherapyMuscle invasive bladder cancerClinical stage of diseaseEnzyme inhibitorsAssociated with OSInitiation of therapyInvasive bladder cancerHigh-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)
Moutafi M, Bates K, Aung T, Milian R, Xirou V, Vathiotis I, Gavrielatou N, Angelakis A, Schalper K, Salichos L, Rimm D. High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2024, 12: e009039. PMID: 38857914, PMCID: PMC11168162, DOI: 10.1136/jitc-2024-009039.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsProgrammed cell death protein 1Associated with OSCell lung cancerTissue microarray spotsTissue microarrayValidation cohortLung cancerNon-small cell lung cancer treated with immune checkpoint inhibitorsAssociated with resistance to immunotherapyCell death protein 1Resistance to immunotherapyAssociated with PFSProgression-free survivalSecreted frizzled-related protein 2Cox proportional-hazards model analysisCheckpoint inhibitorsImmunotherapy strategiesTumor compartmentsRetrospective cohortDiscovery cohortLong-term benefitsPatientsCD68Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 34: 6940-6952. PMID: 38536464, PMCID: PMC11399284, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeThree- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Lerner S, Thompson I, Dorff T, Lara P, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. European Urology Oncology 2024, 7: 1097-1104. PMID: 38523017, PMCID: PMC12037053, DOI: 10.1016/j.euo.2024.03.001.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerProstate-specific antigenAndrogen deprivation therapyProstate-specific antigen levelOverall survivalProstate cancerDeprivation therapyComplete responseAntigen levelsNo responseTreatment of metastatic hormone-sensitive prostate cancerLow prostate-specific antigen levelsResponse to androgen deprivation therapyAssociated with improved OSPSA responsePhase 3 randomized trialPhase 3 clinical trialsEarly identification of patientsAssociated with OSHigher risk of deathIdentification of patientsResponse to treatmentRisk of deathOS associationEvaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.
Saliby R, Xie W, Wells J, Saad E, Eid M, Labaki C, Semaan K, Ferrier E, Lemelin A, Suárez C, Ruiz-Morales J, Powles T, Wood L, Ebrahimi H, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study. Journal Of Clinical Oncology 2024, 42: 400-400. DOI: 10.1200/jco.2024.42.4_suppl.400.Peer-Reviewed Original ResearchTime to next therapyTime to treatment failureInternational mRCC Database ConsortiumImmune checkpoint inhibitorsMetastatic renal cell carcinomaOverall survivalIntermediate endpointsHazard ratioInternational mRCC Database Consortium risk groupTreated with immune checkpoint inhibitorsDual immune checkpoint inhibitorsICI startICI-based regimensAssociated with OSAssociation of OSEndpoint of OSRenal cell carcinomaCheckpoint inhibitorsNext therapyMetastatic sitesDrug cessationTreatment failurePrimary endpointCell carcinomaMedian age
2023
The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer
Liu L, Wang Y, Liu T, Rao S, Zeng M. The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer. Abdominal Radiology 2023, 48: 3653-3660. PMID: 37755476, DOI: 10.1007/s00261-023-04048-z.Peer-Reviewed Original ResearchConceptsLocally advanced gastric cancerLargest lymph nodeNeoadjuvant chemotherapyOverall survivalLong-term prognosisTumor responseLN respondersRadical surgeryLymph nodesLargest LNComputed tomographyLocally advanced gastric cancer patientsTumor response to NACTumor response to neoadjuvant chemotherapyGastric cancerResponse to NACResponse to neoadjuvant chemotherapyLN responsePrediction of tumor responseAssessment of tumour response to neoadjuvant chemotherapyPrimary tumor responseAssociated with OSAdvanced gastric cancerProspective clinical trialMultivariate Cox model
2022
Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes
2017
Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).
Oh W, Kandadi H, Sheikh N, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2017, 35: 36-36. DOI: 10.1200/jco.2017.35.7_suppl.36.Peer-Reviewed Original ResearchMinimally symptomatic metastatic castration-resistant prostate cancerOverall survivalPeripheral bloodSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerBaseline prostate-specific antigen levelBlood-based predictive biomarkersPredictive of OS benefitProstate-specific antigen levelCastration-resistant prostate cancerMultivariate Cox proportional hazards regression modelsImmunotherapy sipuleucel-TPB mononuclear cellsAssociated with OSPredictive of OSCox proportional hazards regression modelsFDA-approved immunotherapyProportional hazards regression modelsGene expressionHazards regression modelsGene expression signaturesAssociation of gene expressionMedian OSSipuleucel-TOS benefit
2005
Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer
Guillem J, Chessin D, Cohen A, Shia J, Mazumdar M, Enker W, Paty P, Weiser M, Klimstra D, Saltz L, Minsky B, Wong W. Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. Annals Of Surgery 2005, 241: 829-838. PMID: 15849519, PMCID: PMC1357138, DOI: 10.1097/01.sla.0000161980.46459.96.Peer-Reviewed Original ResearchConceptsLong-term oncologic outcomesRecurrence-free survivalPreoperative combined modality therapyLocally Advanced Rectal CancerCombined modality therapyAdvanced rectal cancerOncological outcomesOverall survivalModality therapyPerineural invasionRectal adenocarcinomaRectal cancerPathological responseTreatment of locally advanced rectal cancerYear recurrence-free survivalLocally advanced rectal adenocarcinomaLong-term oncological resultsPrediction of oncological outcomesPathologic tumor responsePredictive clinicopathological factorsAdvanced rectal adenocarcinomaPositive lymph nodesMedian Follow-UpAssociated with OSTotal mesorectal excision
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply